Our Philadelphia Bydureon drug injury lawyers are evaluating cases involving pancreatic cancer and other serious injuries in type-2 diabetics who have used the drug Bydureon. Bydureon, a once-weekly injectable drug, is an extended-release version of the twice-daily injectable medication, Byetta. Both Byetta and Bydureon are glucagonlike peptide 1 (GLP-1) receptor agonists, or incretin mimetics.
Bydureon has been associated with serious injuries, including:
- hemorrhagic and necrotizing pancreatitis
- pancreatic cancer
- thyroid cancer
- altered kidney function, renal insufficiency, and renal failure
- injection site reactions, including necrosis (tissue death), abscesses, and cellulitis
- wrongful death
Bydureon and Pancreatic Cancer
Natural incretin hormones stimulate the pancreas’s release of insulin to lower blood sugar, a function that is often compromised in type-2 diabetics. Bydureon, as an incretin mimetic, mimics the function of natural incretins, but it may also increase a type-2 diabetic’s risk of pancreatic cancer.
Additional incretin therapy and incretin mimetic drugs include:
- Onglyza (see Philadelphia Onglyza Drug Injury Lawyers)
- Januvia (see Philadelphia Januvia Drug Injury Lawyers)
- Janumet (see Philadelphia Janumet Drug Injury Lawyers)
- Victoza (see Philadelphia Victoza Drug Injury Lawyers)
- Byetta (see Philadelphia Byetta Drug Injury Lawyers)
- Janumet XR
Bydureon Warnings and Studies
On May 1, 2010, the Annals of Pharmacotherapy reported a study that found an association between Bydureon (exenatide extended release) and acute pancreatitis.
In July 2011, the journal Gastroenterology reported results of a study revealing an increased risk of pancreatic cancer in Bydureon (exenatide) users and a 6-fold increase in risk of pancreatitis. The authors concluded that study results raised caution about exenatide’s (Bydureon, Byetta) potential to promote pancreatic cancer.
On March 14, 2013, the FDA published a drug safety communication warning of the potential of incretin mimetics such as Bydureon to increase users’ risk of pancreatitis and pancreatic duct metaplasia.
On April 8, 2013, the National Institutes of Health (NIH) published study results showing an increased risk of acute pancreatitis in users of Bydureon (exenatide). The study also revealed that Bydureon users developed pancreases that were 40% larger than normal size.
Lawsuits filed by Philadelphia Bydureon drug injury lawyers may allege that Bydureon manufacturers Eli Lilly and Company, Amylin Pharmaceuticals, Bristol-Myers Squibb, and AstraZeneca:
- manufactured an unreasonably dangerous and defective drug
- failed to conduct adequate pre-market testing of Bydureon side effects
- failed to provide adequate warnings to physicians and the public about increased risks of pancreatic cancer and other serious injuries related to Bydureon use
- engaged in aggressive false advertising of Bydureon despite knowledge of serious Bydureon side effects
Contact our Philadelphia Bydureon Drug Injury Lawyers
If you or a family member developed pancreatic cancer or another serious injury following use of the type-2 diabetes drug Bydureon, you may be entitled to compensation from the manufacturers. Contact our Philadelphia Bydureon drug injury lawyers, today, to inquire about filing a Bydureon lawsuit.